Journal commentary weighs survodutide kidney findings in hyperfiltration model
The piece in Diabetes, Obesity & Metabolism addresses how renoprotective signals from the dual agonist should be read in that preclinical setting.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 18 20:00 ETSource: Diabetes, obesity & metabolism
The wire
- 01Ye and colleagues published a commentary interpreting survodutide renoprotection data generated in a hyperfiltration model.
- 02Kidney endpoints are a live question for incretin and glucagon receptor co-agonists, and clinicians following survodutide will want the caveats on model choice.
- 03This is commentary rather than a new trial readout, and the underlying evidence remains preclinical.
From the source
Read at pubmed.ncbi.nlm.nih.govInterpreting Survodutide Renoprotection in a Hyperfiltration Model
Diabetes, obesity & metabolism · 2026 Oct 19 · Ye T et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42897119/
